NCT02917187

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of Primary Inherited Erythromelalgia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additional aspects of pain in participants with EM; and to investigate the safety and tolerability of repeat oral dosing of BIIB074 in participants with EM.

Detailed description

This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen.

Conditions

• Primary Inherited Erythromelalgia

Interventions

Type	Name	Description
DRUG	BIIB074	Administered as specified in the treatment arm
DRUG	Placebo	Matched placebo

Timeline

• Start date: 2016-09-09
• Primary completion: 2016-12-27
• Completion: 2017-01-05
• First posted: 2016-09-28
• Last updated: 2018-01-10

Locations

5 sites across 1 country: United States